Current Practice and Safety of Invasive Coronary Function Testing: A Nationwide Multicenter Survey in Japan

日本全国多中心调查:冠状动脉介入功能检查的现状及安全性

阅读:3

Abstract

BACKGROUND: Coronary vasomotor dysfunction-including vasospastic angina and coronary microvascular dysfunction-is a key mechanism underlying ischemia or myocardial infarction with nonobstructive coronary arteries (INOCA/MINOCA). While invasive coronary function testing (CFT) provides important diagnostic insights, its real-world use and safety-especially in emergency settings-remain poorly defined. OBJECTIVES: The purpose of this study was to assess the current practice, diagnostic yield, and safety of CFT, including acetylcholine (ACh) and ergonovine (ERG) provocation tests and coronary microvascular assessments using coronary flow reserve (CFR) and index of microcirculatory resistance (IMR), in Japan. METHODS: We conducted a nationwide cross-sectional survey of 235 institutions affiliated with the Japanese Cardiovascular Intervention and Therapeutics Society. Data on procedure volume, positivity rates, and complications were collected for tests performed between January 2022 and December 2023. RESULTS: Among 6,983 provocation tests, 4,700 were ACh (4,327 elective and 373 emergency) and 2,283 were ERG (2,009 elective and 274 emergency). CFR/IMR was measured in 2,192 cases. Positivity rates were 50.9% for ACh and 32.5% for ERG. Major complications occurred in 1.4% of ACh and 0.4% of ERG tests, with no significant difference between emergency and elective settings. Abnormal CFR/IMR findings were more common in emergency cases (45.9% vs 34.8%; P < 0.001), while complications remained rare (0.05%). CONCLUSIONS: This large-scale survey confirms the feasibility and safety of invasive CFT, even in emergency settings. These findings support its broader adoption in the diagnostic workup of INOCA and MINOCA.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。